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SECRETIN IS A major gut hormone that regulates pancreatic water and bicarbonate secretion (9, 10, 14) . Secretin is released from S cells of the upper small intestine in response to luminal stimuli, including gastric acid, fatty acid, bile salts, and other dietary elements (10) . Some neuropeptides and neurotransmitters, such as pituitary adenylate cyclase-activating polypeptide (PACAP; see Ref. 27 ), gastrin-releasing peptide (GRP; see Ref. 30 ), or serotonin (29) , also stimulate or are involved in the release of secretin. It has been reported that secretin-releasing peptides exist in both the upper small intestine (31) and pancreatic juice (32) to mediate the release of endogenous secretin in the dog (42) and rat (32) . Chang et al. (8) have purified two secretinreleasing factors (SRFs) from canine pancreatic juice. Both are 14-kDa polypeptides that are structurally homologous to canine pancreatic phospholipase A 2 (PLA 2 ). These two secretin-releasing peptides (8) and purified porcine pancreatic PLA 2 (4) were found to stimulate secretin release from STC-1 cells and S cellenriched cell preparations isolated from rat duodenal mucosa. However, it has not been studied whether the secretin-releasing peptide activity in the small intestine is attributed to PLA 2 .
It has become evident that PLA 2 are a heterogeneous family of lipolytic enzymes that can be classified into at least five subtypes of mammalian origin (12) . Group I, II, and III PLA 2 are low-molecular-weight PLA 2 of 14 kDa referred to as secretory, extracellular enzymes. Group IV PLA 2 are high-molecular-weight PLA 2 of 60-110 kDa referred to as cytosolic PLA 2 , whereas bee venom PLA 2 constitute the group V enzyme. Recent data have indicated that PLA 2 play a number of important roles in cells and tissues (13) . Pancreatic PLA 2 belongs to the group I PLA 2 and plays a central role in the digestion of dietary and biliary phospholipids. It is also involved in stimulation of cell growth (15) , contraction of smooth muscle (41) , and regulation of progesterone (39) and prostaglandin (44) release. We hypothesized that PLA 2 may function as a modulator of intestinal endocrine cells to play an important role in stimulation of secretin release in the rat.
The aim of the present study was to investigate the distribution of phospholipase A 2 -like immunoreactivity (PLA 2 -LI) in the gastrointestinal tract and the pancreas, the release of PLA 2 from the upper small intestine and pancreas after duodenal perfusion of acid, the effect of a specific anti-PLA 2 serum (anti-PLA 2 ) on pancreatic exocrine secretion and the release of secretin in response to duodenal acidification, and the effect of the antibody on SRF activity in duodenal acid perfusate in anesthetized rats.
MATERIALS AND METHODS
Animal preparation. Male Sprague-Dawley rats weighing between 220 and 280 g were fasted for 24 h with free access to drinking water before surgery. Under anesthesia with intraperitoneal injection of 25% urethane at a dose of 120 mg/100 g body wt, a midline abdominal incision was made. A polyethylene tube (ID 3.0 mm, OD 4.0 mm) for duodenal infusion was inserted in the proximal duodenum 5 mm distal to the pylorus through the stomach followed by ligation of the pylorus. A jugular vein catheter was prepared with a polyethylene tube (PE-50, ID 0.58 mm, OD 0.96 mm). The tube was kept patent by infusion of 0.15 M NaCl at a rate of 1 ml/h. In the donor-recipient study, a 20-cm upper small intestinal loop was made by placing an additional cannula (ID 3.0 mm, OD 4.0 mm) in the jejunum 15 cm distal to the ligament of Treitz for collection of the perfusate. A polyethylene tube (PE-10, ID 0.28, OD 0.61 mm) was inserted in the pancreatic duct via the ampulla for collection of pancreatic juice. A second PE-10 tube was inserted in the bile duct proximal to the pancreatic duct for diversion of bile to the exterior. The abdominal wound was covered by a piece of wet gauze soaked with isotonic saline.
Experimental design. Experiments were performed 30 min after surgery. After 90-min collection of basal pancreatic secretion, 0.02 N HCl in saline was infused intraduodenally at a rate of 4.5 ml/h for 60 min in five rats. To study the effect of anti-PLA 2 on acid-induced pancreatic exocrine secretion and the release of secretin, anti-PLA2 at 0.1, 0.3, and 0.5 ml/rat was injected via the jugular vein 30 min before duodenal infusion of acid in five rats each. Normal rabbit serum (NRS) was injected intravenously at 0.5 ml/rat before intraduodenal infusion of 0.02 N HCl began in five rats as controls. The antibody used in this experiment was the same as the one used for RIA for PLA 2 described below.
In the donor-recipient study, the upper small intestinal loop was washed with 40 ml of warm 0.15 M NaCl followed by perfusion of the loop with 0.02 N HCl at 0.3 ml/min for 1.5 h while both bile and pancreatic juice were diverted. The acidperfusate was continuously collected from the jejunal cannula in an ice-chilled beaker and then centrifuged at 3,000 g and 4°C for 25 min. The supernatant solution was lyophilized and concentrated 10-fold, adjusted to pH 7.0, and then incubated with anti-PLA 2 or NRS (1:10) at 37°C for 30 min. The materials were further filtered through an Amicon PM-10 membrane (Grace, Danvers, MA) to remove the antibody and antibody-antigen complex. The filtrate was reinfused in the upper small intestine of recipient rats after a 90-min collection of basal pancreatic secretion.
To determine the release of PLA 2-LI by duodenal acidification, an aliquot of 2 ml of the perfusate collected during the basal period or duodenal acid perfusion was mixed with 0.1 ml of 2% BSA in saline and stored at Ϫ20°C before determination of PLA 2-LI by RIA. To determine if PLA2 has different susceptibility in the duodenal lumen during saline and acid perfusion, porcine pancreatic PLA2 at a concentration of 1 ng/ml was added to perfusion solution of saline or acid. After a 30-min perfusion with saline alone in the basal period, PLA2 in saline, HCl alone, or PLA2 with or without HCl was perfused intraduodenally in three groups of three rats each as described above. The perfusate was collected during basal and experimental periods in 30-min intervals. The perfusate was treated and stored as described below for RIA of PLA 2. To determine the distribution of PLA2 in the gastrointestinal tract, five rats were killed by cervical dislocation after 24 h of fasting. The stomach, duodenum, jejunum-ileum, colon, and pancreas were immediately taken and washed separately with 0.15 M NaCl at 4°C. Each tissue was homogenized in 5 vol of 10 mM Tris ⅐ HCl, pH 7.4, at 4°C using a Polytron at maximum output for 30 s. The homogenate was centrifuged at 108,000 g for 1 h at 4°C. The supernatant solution was stored at Ϫ70°C for RIA of PLA 2.
RIA of PLA2. RIA of PLA2 was carried out using a specific anti-PLA2 serum raised in our laboratory. The antiserum was raised in New Zealand White rabbits by immunization with purified porcine pancreatic PLA2 (4) emulsified in Freund's adjuvant and boosted monthly with the enzyme emulsified in Freund's incomplete adjuvant (5, 6) . After five booster injections, the titer of the antibody increased to 1:10 6 . The antibody is specific for PLA2-I and has no cross-reaction with any known gastrointestinal regulatory peptides or islet hormones, including rat secretin, CCK-8, human gastrin-17-I, glucagon, porcine GRP, insulin, rat pancreatic polypeptide, vasoactive intestinal peptide, and PACAP-38. The competitive tracer-binding curves with standard PLA 2 and some of these peptides are shown in Fig. 1 . The anti-PLA2 serum also had no cross-reaction with reptilian and bee venom PLA2 (all obtained from Sigma), as shown in Fig. 2 . An RIA method was developed using purified porcine pancreatic PLA 2 as the standard. Purified PLA2 (5 g) was radioiodinated using the chloramine T-catalyzed method (19) . The labeled enzyme was then purified by gel filtration through a Sephadex G-50 superfine column (1.3 ϫ 58 cm) run in 50 mM sodium phosphate, pH 7.5, containing 0.15 M NaCl, 0.5% BSA, and 0.02% NaN 3. Purified 125 I-labeled PLA2 had a specific activity of 260.6 Ci/nmol. The sample or standard was incubated with anti-PLA2 (at 1:10 6 dilution) in 50 mM sodium phosphate, pH 7.0, containing 0.1% BSA and 0.02% NaN3 at 4°C for 48 h. I-PLA2 (5,000 counts/min) was then added, and the reaction mixture was further incubated for 48 h at 4°C. The reaction mixture was then mixed with 30 g of bovine IgG followed with 1.4 mg of insoluble protein A (Sigma) in a final volume of 2 ml. The final reaction mixture was incubated further for 1 h with occasional mixing and then was centrifuged at 1,650 g for 30 min. The supernatant solution (containing free PLA 2 counts) and the pellet (containing antibody-bound PLA2 counts) were separated, and both were counted in a Wallac model 1271 gamma counter with automatic data reduction using the RIACALC software provided by the manufacturer. The assay has a minimum detection limit of 10 pg PLA 2 and intra-and interassay variations of 7 and 9%, respectively.
Determination of pancreatic secretion and plasma concentration of secretin. Pancreatic juice was collected continuously by inserting the pancreatic duct cannula in a glass micropipette (Drummond Scientific, San Francisco, CA) in 30-min intervals. The volume of the fluid retained in the micropipette was determined by measuring the length of fluid filling the micropipette (3.85 l/cm), as described previously (28, 31) . After the measurement of the fluid volume, the content of the micropipette was blown in a 0.2-ml microcentrifuge tube using a rubber bulb. A sample of 10 l was immediately taken to determine the bicarbonate concentration using a 965 Carbon Dioxide Analyzer (Ciba-Corning Diagnostics, Halstead Essex, UK). At the end of each experiment, blood samples were drawn immediately from the aorta and collected in heparinized glass tubes at 4°C. Plasma was obtained and stored at Ϫ70°C. Plasma secretin level was measured by the RIA method described previously (6).
Data analyses.
All values were expressed graphically as means Ϯ SE. The percentage (%) increase in pancreatic secretion over the basal value was calculated by comparison between the values obtained in the last 60-min treatment period and the last 60-min basal period. The statistical differences in these data were analyzed using one-way ANOVA. Tukey's post hoc test was applied for multiple comparisons of the means. A difference between two means with P values of Ͻ0.05 is regarded as statistically significant. 2 in the gastrointestinal tract and the pancreas. RIA of PLA 2 in the tissue extracts indicated that PLA 2 distributed throughout the gastrointestinal tract and the pancreas ( Table 1 ). The contents of PLA 2 in the pancreas and the small intestine were similar, although PLA 2 in the duodenum was slightly less than that in the jejunum-ileum and the pancreas. PLA 2 in the stomach and the colon was much less compared with that in the pancreas and the small intestine.
RESULTS

Distribution and release of PLA
Perfusion of the upper small intestinal loop with 0.02 N HCl significantly increased the concentration of PLA 2 in the intestinal perfusate (from 0.42 Ϯ 0.04 to 1.49 Ϯ 0.63 ng/ml, n ϭ 5, P Ͻ 0.05; Fig. 3 ). When PLA 2 in saline was perfused intraduodenally, there was no time-dependent decrease in PLA 2 immunoreactivity in the perfusate. As shown in Table 2 , the average concentration of PLA 2 -LI of the nine samples collected was 1.05 Ϯ 0.14 ng/ml, which was 0.93 ng/ml above the average basal concentration, indicating a 93% recovery of the exogenous PLA 2 . Similarly, the average concentration of PLA 2 -LI found in the perfusate of PLA 2 with Values are means Ϯ SE of 5 rats in each tissue. Phospholipase A2 (PLA2)-like immunoreactivity was determined by RIA. Fig. 3 . Release of pancreatic PLA2 from the upper small intestine (A) and the pancreas (B) in response to duodenal acidification. Basal, basal PLA2 level after 24 h of fasting; HCl, 0.02 N HCl (4.5 ml/h id). Upper small intestinal acid perfusate and pancreatic juice were continuously collected for 60 min during acid perfusion. PLA2 levels were determined by RIA. Values are means Ϯ SE from 5 rats in each group. *P Ͻ 0.05 compared with basal values. or without HCl (2.08 Ϯ 0.20 ng/ml) was 0.98 ng/ml over that of the HCl control, corresponding to a 98% recovery of exogenous PLA 2 . Although acid perfusion did not influence the PLA 2 concentration in pancreatic juice (Fig. 3) , the output of PLA 2 was significantly increased because the volume of pancreatic fluid, as shown in Fig. 4 , was markedly elevated (72% over basal secretion) in response to acid.
Effect of anti-PLA 2 on pancreatic exocrine secretion and the release of secretin in response to duodenal acidification. Basal pancreatic secretion of fluid (17.6 Ϯ 3.6 l/30 min) and bicarbonate (0.54 Ϯ 0.14 eq/30 min) was stable during the study period. Duodenal infusion of 0.02 N HCl significantly increased pancreatic secretion of fluid (73.2 Ϯ 10.7% over basal secretion, P Ͻ 0.01) and bicarbonate output (144.1 Ϯ 27.8% over basal, P Ͻ 0.01). Intravenous injection of anti-PLA 2 at 0.1, 0.3, and 0.5 ml did not influence basal pancreatic exocrine secretion (data not shown) but dose-dependently inhibited the acid-stimulated pancreatic fluid and bicarbonate secretion (Fig. 4) . The plasma level of secretin also decreased in a dose-related manner after anti-PLA 2 administration (Fig. 5) . NRS did not influence either pancreatic secretion or the release of secretin (Figs. 4 and 5) .
Pancreatic secretion and release of secretin in response to intestinal acid perfusate with and without preincubation with anti-PLA 2 in recipient rats. Intraduodenal administration of intestinal acid perfusate increased pancreatic secretion of fluid volume (72.2 Ϯ 11.3% over basal secretion) and bicarbonate output (140.7 Ϯ 28.9% over basal) and caused an elevation of plasma secretin concentration to 6.2 Ϯ 1.2 pM. To test if PLA 2 -LI present in the duodenal acid perfusate contributes to this SRF activity (30) , the perfusate was preincubated with either NRS or anti-PLA 2 and then ultrafiltrated. As shown in Fig. 6 , intraduodenal perfusion in the recipient rats of the donor acid perfusate, which was preincubated with NRS, resulted in an increase in plasma secretin concentration to 5.6 Ϯ 0.8 pM and an increase of pancreatic secretion of fluid volume by 61.5 Ϯ 7.6% and bicarbonate output by 108.7 Ϯ 12.7% over basal. These increases were not significantly different from those produced by the untreated perfusate described above. In contrast, the acid perfusate preincubated with anti-PLA 2 failed to elevate plasma secretin concentration (1.5 Ϯ 0.6 pM) and produced only a small increase in pancreatic secretion of fluid volume (10.1 Ϯ 5.1% over basal) and bicarbonate output (44.0 Ϯ 19.0% over basal) in the recipient rats. Thus anti-PLA 2 -treated perfusate elicited less fluid volume and bicarbonate output by 81.2 Ϯ 8.9 and 62.0 Ϯ 9.9%, respectively, than NRS-treated perfusate.
DISCUSSION
The results of the present study have indicated that pancreatic PLA 2 is distributed in the small intestine mucosa and may function as an SRF during duodenal acidification. Our previous studies (28, 31) have shown that duodenal acidification in the rat elicited the release of an SRF activity in the duodenal lumen that can be recovered from the acid perfusate. Infusion of a concentrate of ultrafiltrated duodenal acid perfusate in the duodenum of a recipient rat stimulates the release of secretin and pancreatic exocrine secretion of fluid and bicarbonate. We have demonstrated in the present study that pancreatic PLA 2 -LI is present in the luminal perfusate, and its concentration is increased upon duodenal acidification in the rat. Because exogenous PLA 2 in saline or acid perfused intraduodenally did not result in different recovery of PLA 2 -LI (Table 2) , the increase in PLA 2 -LI concentration must be the result of an increase in the release of endogenous PLA 2 . Immunoneutralization of PLA 2 with a specific anti-PLA 2 serum result in a significant inhibition of the increases of plasma secretin concentration and pancreatic exocrine secretion of fluid and bicarbonate elicited by duodenal acidification. Pretreatment of the concentrated perfusate from donor rats with anti-PLA 2 resulted in a substantial decrease in the SRF activity of the perfusate. The observation suggests that a PLA 2 -LI in the acid perfusate is a constituent of the SRF activity and thus corroborates well our previous observations that canine (8) and porcine (4) pancreatic PLA 2 stimulate secretin release from secretin-producing cells. The source of the pancreatic PLA 2 -like SRF appeared to be in the upper small intestine as pancreatic juice was diverted in both donor and recipient rats in the present study. This view is supported by the findings that pancreatic PLA 2 is widely distributed in the intestine and is released in the duodenal lumen upon acid perfusion during pancreatic juice diversion. It should be noted that the presence of pancreatic PLA 2 in nonpancreatic tissues, including the stomach and the intestine, has been documented previously (25, 37, 40, 45) . mRNA for PLA 2 -I has been detected in the mucosa of human ileum (34) and guinea pig stomach (47) . Moreover, luminal secretion of PLA 2 activity has been documented in the rat small intestine (1, 2) and guinea pig gastric juice (45) . It should be noted that PLA 2 -LI in the intestinal acid perfusate could not be derived from gastric juice as the pylorus was ligated in the present study. In addition, it is unlikely that the detection of PLA 2 -like immunoreactivity in the intestinal lumen was the result of mucosal damage because we infused a diluted acid (0.02 N HCl) so that, during acid infusion, the luminal pH was maintained between 3.0 and 4.0 because of duodenal bicarbonate secretion (unpublished observation). Moreover, we have previously shown by electron microscopy in dogs that duodenal perfusion with 0.1 N HCl does not cause mucosal damage (7) .
The mechanism of action of pancreatic PLA 2 as an SRF is not clear at present. Although a small amount of IgG has been shown to be transported across human jejunal mucosa (22) , it is unlikely that a sufficient amount of anti-PLA 2 is transported to the intestinal lumen to inhibit the release of secretin and exocrine pancreatic secretion upon duodenal acidification. An alternative explanation is that PLA 2 may also be released and acts locally at the basolateral interstitial space of the intestinal mucosa. Our previous study (28) indicated that the release and action of SRF during duodenal acidification are neurally mediated, depending on the vagal afferent pathway. It is possible that, in addition to the release in intestinal lumen, PLA 2 is also released locally and acts on mucosal vagal afferent fibers to stimulate secretin release. The presence of a PLA 2 -specific receptor (11, 26) and action of secretory PLA 2 in neurons has been documented (37) . On the other hand, luminally released PLA 2 may penetrate the intestinal mucosa and acts on S cells directly and/or indirectly through the vagal afferent pathway. The neural action of PLA 2 , either locally released or derived from the lumen, would then be sensitive to anti-PLA 2 that reaches the lamina propria in the intestinal mucosa where mucosal afferent nerve fibers are found. However, these modes of action by PLA 2 remain hypothetical and may be tested in our future study.
It is not unusual for pancreatic PLA 2 to be involved in the regulation of secretin release. PLA 2 are a family of lipolytic enzymes that release fatty acid specifically from the sn-2 position of phospholipids and are classified into several groups according to their primary structures (12, 13, 46) . Several important functions have been identified for various PLA 2 , including phospholipid digestion and metabolism, host defense, and signal transduction (13) . Pancreatic PLA 2 is a group I PLA 2 and a well-defined digestive enzyme. The results of recent studies have indicated that this enzyme is also present in nonpancreatic tissues (36, 40) and is involved in regulation of other cellular functions, including secretion of progesterone (39) , prostaglandin production (44), gene expression of type II PLA 2 (24) , stimulation of smooth muscle contraction (23, 41) , and stimulation of cell proliferation (15) (16) (17) . Thus our observations that pancreatic PLA 2 stimulates secretin release from secretin-producing cells (4, 8) and may function as an SRF (present study) have provided an addition to the functional list of this enzyme. It is not surprising, therefore, that pancreatic PLA 2 is involved in the regulation of secretin release.
It should be noted that, based on the results of this study, we could not rule out the possibility that other SRF exist and also play a role in acid-stimulated release of secretin. This is quite analogous to that of CCK-releasing factors in regulation of the release of CCK (35, 38) . Two luminal CCK-releasing factors, luminal CCK-releasing factor (43) and diazepam-binding inhibitor (18) , have been purified, sequenced, and shown to release CCK and elevate pancreatic protein secretion through a CCK-dependent mechanism. In addition, monitor peptide isolated from rat pancreatic juice (21) also stimulated the release of CCK from CCK-producing cells (3, 33) and from rats in vivo (20, Fig. 6 . Release of secretin and pancreatic secretion in response to upper small intestinal acid perfusate preincubated with anti-PLA2 in recipient rats. The upper small intestine was perfused with 0.02 N HCl at 0.3 ml/min for 1.5 h while bile and pancreatic juice were diverted in donors. The acid perfusate was concentrated 10-fold and incubated with anti-PLA2 or NRS (1:10) at 37°C for 30 min. The materials were filtered through a PM-10 Amicon membrane to remove anti-PLA2 and reinfused into the recipient rats. A: volume. B: bicarbonate output. C: secretin. Values are means Ϯ SE from 5 rats in each group. *P Ͻ 0.05 and **P Ͻ 0.01 vs. basal pancreatic secretion or basal plasma concentration of secretin. 21). We have attempted to isolate SRF from rat intestinal acid perfusate. So far, we have identified a few fractions possessing SRF activity that have no crossreaction with PLA 2 antibody and have chromatographic properties different from that of PLA 2 (unpublished observation). Therefore, it is likely that SRF also exists in multiple forms to mediate acid-stimulated secretin release.
In summary, the results of the present study demonstrate that pancreatic PLA 2 is distributed throughout the gastrointestinal tract and was abundant in the pancreas and the small intestine. Duodenal infusion of diluted acid stimulated the release of PLA 2 from the upper small intestine to elicit the secretion of secretin, which was abolished by intravenous administration of anti-PLA 2 . SRF activity in duodenal acid perfusate from donor rats was also completely suppressed by preincubation with anti-PLA 2 . These results strongly suggested that pancreatic PLA 2 in the small intestine is an SRF in regulation of the release of secretin and pancreatic exocrine secretion in response to duodenal acidification in the rat.
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